Key Takeaways
- • Activist hedge fund Toms Capital, led by Benjamin Pass, has quietly built a significant stake in McCormick & Co. during the second quarter of 2026, following the company's announcement of a $44.8 billion acquisition of Unilever's food business in late March.
- • The combined entity will create a roughly $65 billion sauces-and-spices group spanning brands including Hellmann's and French's, but the deal is not expected to close until mid-2027, creating an extended regulatory review and shareholder approval process.
- • McCormick has underperformed the State Street Consumer Staples Index by 15% since the Unilever deal announcement, while the market applies a "deal overhang" discount that compresses the company's traditional valuation premium due to timing risk, integration uncertainty, and management distraction concerns.
- • The extended timeline until mid-2027 creates material opportunity cost for shareholders, as the longer regulatory and integration window increases the probability of delays, conditions, or strategic drift that historically widens valuation discounts during multi-year acquisition periods.
Summary
Activist hedge fund Toms Capital has established a notable position in McCormick & Co. (ticker: MKC) during the second quarter of 2026, according to Reuters reporting on individuals familiar with the matter. The timing of Toms Capital's investment follows closely on McCormick's announcement in late March of its acquisition of Unilever's food business—a transformational $44.8 billion transaction that will merge the spice maker with Unilever's portfolio of sauces and condiments, creating an integrated entity with approximately $65 billion in annual revenue across iconic brands including Hellmann's, French's, and McCormick's core spice offerings.
The extended deal timeline presents the core thesis for activist positioning. McCormick shareholders will not see transaction closure until mid-2027 at the earliest, creating an approximately 18-month window of regulatory scrutiny, potential conditions, and mandatory shareholder approval. This extended period introduces what market participants term a "deal overhang"—a valuation discount applied by investors who factor in the opportunity cost of extended deal execution risk. Since the Unilever acquisition announcement, McCormick shares have underperformed the State Street Consumer Staples Index by 15 percentage points, while Unilever itself has lagged the MSCI Europe Consumer Staples Index by 8 percentage points.
Historically, McCormick has traded at a premium valuation relative to consumer-staples peers due to the defensive characteristics of its product portfolio, which maintains demand resilience during consumer spending pullbacks. However, the extended deal timeline and associated integration risks have shifted investor focus from product fundamentals to transaction execution risk and management bandwidth. The longer the regulatory period extends, the greater the probability of unforeseen delays or strategic complications, and the more leadership attention becomes consumed by deal mechanics rather than core business optimization. This dynamic has compressed McCormick's traditional staples-sector valuation advantage and created the type of mispricing opportunity that activist investors typically target for value realization.
The extended deal timeline presents the core thesis for activist positioning. McCormick shareholders will not see transaction closure until mid-2027 at the earliest, creating an approximately 18-month window of regulatory scrutiny, potential conditions, and mandatory shareholder approval. This extended period introduces what market participants term a "deal overhang"—a valuation discount applied by investors who factor in the opportunity cost of extended deal execution risk. Since the Unilever acquisition announcement, McCormick shares have underperformed the State Street Consumer Staples Index by 15 percentage points, while Unilever itself has lagged the MSCI Europe Consumer Staples Index by 8 percentage points.
Historically, McCormick has traded at a premium valuation relative to consumer-staples peers due to the defensive characteristics of its product portfolio, which maintains demand resilience during consumer spending pullbacks. However, the extended deal timeline and associated integration risks have shifted investor focus from product fundamentals to transaction execution risk and management bandwidth. The longer the regulatory period extends, the greater the probability of unforeseen delays or strategic complications, and the more leadership attention becomes consumed by deal mechanics rather than core business optimization. This dynamic has compressed McCormick's traditional staples-sector valuation advantage and created the type of mispricing opportunity that activist investors typically target for value realization.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.